Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout? [Investor's Business Daily]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Investors Business Daily
Related news 3/05/2020 Want to learn how to trade stocks successfully? First examine fundamentals. And keep these seven key words on Wall Street... Is Merck Stock A Buy As Coronavirus Worries Shake Up Pharma Stocks? The No. 1 Pharma Stock Just Topped A Buy Point — Is BMY Stock A Buy? Travel Curbs Tighten; Fiscal Packages Multiply: Virus Update Alnylam Unveils Powerhouse Match-Up To Tackle Coronavirus Outbreak These 4 Pharma Stocks Are Outplaying 90% Of The Stock Market The Biggest Biotech Is Forming A Flat Base — But Is Amgen Stock A Buy? Coronavirus News: As Covid-19 Infects Stock Market, Economy And Business Face Test Emergency Measures Go Global As Cases Top 90,000: Virus Update Gilead Sciences ( GILD ) is attempting to alter its fortunes through the $4.9 billion acquisition of immuno-oncology biotech company Forty Seven ( FTSV ). But analysts are split on whether the massive effort will be enough to outstrip an ongoing decline in Gi
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at UBS Group AG from $70.00 to $96.00. They now have a "neutral" rating on the stock.MarketBeat
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Mizuho from $90.00 to $100.00. They now have an "outperform" rating on the stock.MarketBeat
- Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Daiwa America to a "hold" rating.MarketBeat
- GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study [Yahoo! Finance]Yahoo! Finance
- How Gilead Is Driving Global Health Equity And Innovation [Forbes]Forbes
GILD
Earnings
- 11/6/24 - Beat
GILD
Sec Filings
- 11/20/24 - Form 8-K
- 11/15/24 - Form 424B5
- 11/13/24 - Form FWP
- GILD's page on the SEC website